The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | CHIP & CCUS: considerations for treating these entities and future directions
In this video, Mrinal Patnaik, MBBS, Mayo Clinic, Rochester, MN, shares his thoughts on whether clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) should be treated, and factors to consider when thinking about treating these entities. Dr Patnaik believes that early interception in higher-risk cases is the goal for the future. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, do I believe? The answer is yes. Are we there to do it right now? The answer is no. So I do think that some of the CHIP or CCUS precursors that we understand are high risk, high risk for evolution into blood cancers are the ones where early detection and interception play a role. The vast majority of CHIP that you see in aging individuals are not going to progress to leukemia, how they interact with other comorbidities, including heart disease, needs more definition...
So, do I believe? The answer is yes. Are we there to do it right now? The answer is no. So I do think that some of the CHIP or CCUS precursors that we understand are high risk, high risk for evolution into blood cancers are the ones where early detection and interception play a role. The vast majority of CHIP that you see in aging individuals are not going to progress to leukemia, how they interact with other comorbidities, including heart disease, needs more definition. And especially if treatments have elements of side effects, you do not want to make the cure of disease more grievous than the endurance of the same. But this higher risk population where progression is likely to happen over the next several months, if we can detect them and we can intervene, intercept, whether it’s with medications or different modalities such as vaccines against the mutations, immunotherapy. I think that would be a dream come true, hopefully in the next few years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
